StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

Latest, Q4 2025
26
Period ended Dec 31, 2025
Change on a year earlier
0.0%
26 in Q4 2024
History
12 quarters
Since Q1 2023
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up pifeltro (doravirine — hiv-1 nnrti) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck Pifeltro (doravirine — HIV-1 NNRTI) — U.S. sales ($M) ($M), quarterly Q1 2023–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_pifeltro_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.